Advanced pancreatic Neuroendocrine Tumors: mTOR Inhibitor Afinitor® (Everolimus) receives EU Approval

被引：0
|
作者：
不详
机构：
来源：
VISZERALMEDIZIN | 2011年 / 27卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：403 / 403
页数：1
相关论文
共 50 条
  • [31] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Mojun Zhu
    Julian R. Molina
    Grace K. Dy
    Gary A. Croghan
    Yingwei Qi
    James Glockner
    Lorelei J. Hanson
    Michelle M. Roos
    Angelina D. Tan
    Alex A. Adjei
    Investigational New Drugs, 2020, 38 : 1755 - 1762
  • [32] Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
    Berardi, R.
    Torniai, M.
    Pusceddu, S.
    Spada, F.
    Brizzi, M. P.
    Ibrahim, T.
    Antonuzzo, L.
    Ferolla, P.
    Panzuto, F.
    Silvestris, N.
    Partelli, S.
    Bongiovanni, A.
    Zichi, C.
    Riva, N.
    Rinzivillo, M.
    NEUROENDOCRINOLOGY, 2016, 103 : 77 - 77
  • [33] RETRACTED ARTICLE: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients
    Jun Yao
    Jian-yao Wang
    Yi Liu
    Bin Wang
    Ying-xue Li
    Ru Zhang
    Li-Sheng Wang
    Lei Liu
    Medical Oncology, 2014, 31
  • [34] Retraction Note to: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients
    Jun Yao
    Jian-yao Wang
    Yi Liu
    Bin Wang
    Ying-xue Li
    Ru Zhang
    Li-Sheng Wang
    Lei Liu
    Medical Oncology, 2015, 32
  • [35] Efficacy and Safety of Everolimus As Long-Term Treatment in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors
    Lee, Lingaku
    Igarashi, Hisato
    Hijioka, Masayuki
    Ueda, Keijiro
    Fujiyama, Takashi
    Tachibana, Yuichi
    Kawabe, Ken
    Ito, Tetsuhide
    GASTROENTEROLOGY, 2015, 148 (04) : S393 - S393
  • [36] Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response
    Alors-Perez, Emilia
    Pedraza-Arevalo, Sergio
    Blazquez-Encinas, Ricardo
    Garcia-Vioque, Victor
    Agraz-Doblas, Antonio
    Yubero-Serrano, Elena M.
    Sanchez-Frias, Marina E.
    Serrano-Blanch, Raquel
    Galvez-Moreno, Maria angeles
    Gracia-Navarro, Francisco
    Gahete, Manuel D.
    Arjona-Sanchez, Alvaro
    Luque, Raul M.
    Ibanez-Costa, Alejandro
    Castano, Justo P.
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (01):
  • [37] Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms
    Lee, Lingaku
    Ito, Tetsuhide
    Igarashi, Hisato
    Ueda, Keijiro
    Fujiyama, Takashi
    Kawabe, Ken
    Ogawa, Yoshihiro
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2017, 24 (02) : 95 - 102
  • [38] The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
    Zitzmann, Kathrin
    De Toni, Enrico N.
    Brand, Stephan
    Goeke, Burkhard
    Meinecke, Jennifer
    Spoettl, Gerald
    Meyer, Heinrich H. D.
    Auernhammer, Christoph J.
    NEUROENDOCRINOLOGY, 2007, 85 (01) : 54 - 60
  • [39] Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors
    Kulke, Matthew H.
    SEMINARS IN ONCOLOGY, 2013, 40 (01) : 75 - 83
  • [40] Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors
    Raj, Nitya
    Reidy-Lagunes, Diane
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (01) : 119 - +
12345